[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelet-recovery-after-umbilical-cord-blood-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelet-recovery-after-umbilical-cord-blood-transplantation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100646130","early-phase-1-efficacy-and-safety-of-megalt-injection-for-platelet-recovery-after-umbilical-cord-blood-transplantation-100646130",false,"NCT07696767","Efficacy and Safety of MegaLT Injection for Platelet Recovery After Umbilical Cord Blood Transplantation","Study of the Efficacy and Safety of MegaLT Injection for Promoting Platelet Recovery After Umbilical Cord Blood Transplantation","Inclusion Criteria:\n\n* Age ≥18 years, male or female.\n* Patients with a definite diagnosis of hematologic malignancy who are undergoing umbilical cord blood transplantation.\n* Patients at day 14 after umbilical cord blood transplantation.\n* ECOG performance status ≤2.\n* Patients who voluntarily agree to participate in this clinical trial, fully understand the study content, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with relapse of any malignant tumor.\n* Pregnant or lactating women.\n* Patients with severe infection or severe cardiac, hepatic, pulmonary, renal, neurologic, or metabolic disease.\n* Patients with a history of severe thrombotic events or known risk factors for thrombosis. Exception: participants for whom the investigator determines that the potential benefit of study participation outweighs the potential risk of thromboembolic events.\n* Patients with uncontrolled infectious disease or other serious diseases, including but not limited to infection such as HIV positivity, congestive heart failure, unstable angina, cardiac arrhythmia, psychosis, social circumstances that would limit compliance with study requirements, or any condition that the treating physician considers may pose unpredictable risks.\n* Patients with active hepatitis B or hepatitis C.\n* Patients who have previously received organ transplantation or are planning to receive organ transplantation, except for hematopoietic stem cell transplantation.\n* Patients who participated in another clinical study and used any investigational drug or device within 30 days before the baseline visit. Participation in observational studies is allowed.\n* Patients considered by the investigator to be unsuitable for participation in this clinical trial for any other reason.","ALL","18 Years",{"count":19,"type":20},7,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","This is a single-arm, early safety and feasibility exploratory study to evaluate the efficacy and safety of MegaLT Injection in promoting platelet recovery after umbilical cord blood transplantation. Adults with malignant hematologic diseases who undergo umbilical cord blood transplantation will receive a single intravenous infusion of MegaLT Injection on day 14 after transplantation. Two dose levels will be evaluated sequentially, and platelet recovery, platelet transfusion requirements, and safety outcomes will be assessed.",[26,27,28],"Thrombocytopenia","Hematologic Malignacies","Platelet Recovery After Umbilical Cord Blood Transplantation",[30,31,32,33,26],"MegaLT Injection","Umbilical Cord Blood Transplantation","Platelet Recovery","Platelet Engraftment","NOT_YET_RECRUITING","2026-07-09",{"date":37,"type":38},"2026-07-10","ACTUAL",{"date":40,"type":20},"2026-07-31",{"date":42,"type":20},"2027-06-30",{"name":44,"class":45},"Anhui Provincial Hospital","OTHER_GOV",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100502524","avatrombopag-for-platelet-recovery-post-ucbt-in-patients-with-bone-marrow-failure-disease-100502524","NCT05823376","Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease","Efficacy and Safety of Avatrombopag for Platelet Recovery After Unrelated Cord Blood Transplantation in Patients With Bone Marrow Failure Disease: a Single-center, Single-arm, Phase II Trial","AVA","Inclusion Criteria:\n\n* Age ≥12 years old, male or female;\n* Patients diagnosed with bone marrow failure disease including aplastic anemia (AA), Fanconi anemia (FA), paroxysmal nocturnal hemoglobinuria (PNH) and undergoing UCBT;\n* ECOG score ≤2;\n* Voluntary participation in this clinical trial, patients fully understand the trial content and sign the informed consent；\n\nExclusion Criteria:\n\n* Pregnant or lactating women；\n* Known allergy to Avatrombopag;\n* A history of severe thrombotic events or known risk factors for thrombosis or active thromboembolism requiring anticoagulation;\n* A history of platelet dysfunction or bleeding prone disease or severe bleeding (requiring more than 2 units of red blood cell infusion or a hematocrit drop of ≥10%) within 7 days prior to screening;\n* Chronic active hepatitis B and C;\n* Repeat or multiple transplantation or multiple organ transplantation;\n* HIV positive, EBV-DNA positive, CMV-DNA positive;\n* Have severe infection or complicated with serious heart, liver, lung, kidney, neurological or metabolic diseases;\n* A serious adverse event (Level 4 or 5) as defined by the Standard General Terminology for Adverse Events Version 4.0 occurred during the pre-treatment period;\n* Participants participate in another clinical study with any exploratory drug or device within 30 days prior to baseline visit; Observational studies are allowed;\n* Subjects with cognitive impairment or uncontrolled mental illness;\n* Subjects and\u002For authorized family members to refuse treatment with Avatrombopag;\n* Those who are judged by the researchers as not suitable for inclusion (such as accompanying medical history, which may affect the safety of the subjects or it is estimated that the treatment cannot be adhered to due to financial problems).","12 Years",{"count":56,"type":20},40,"28 Days","OBSERVATIONAL","To evaluate the efficacy and safety of Avatrombopag for platelet recovery after unrelated cord blood transplantation (UCBT) in patients with bone marrow failure disease",[28],[62],"Avatrobopag","RECRUITING","2024-12-30",{"date":66,"type":38},"2024-12-31",{"date":68,"type":38},"2023-05-04",{"date":70,"type":20},"2025-02-28",{"name":44,"class":45},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":72},"100569403","phase-2-romiplostim-n01-for-platelet-recovery-in-adult-hematologic-malignancies-patients-undergoing-ucbt-100569403","NCT06693791","Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT","Efficacy and Safety of a Long-acting Thrombopoietin Receptor Agonist for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing Umbilical Cord Blood Transplantation","Inclusion Criteria:\n\n* Age ≥12 years old, male or female;\n* Patients diagnosed with hematological malignancies and undergoing UCBT;\n* ECOG score ≤2;\n* Voluntary participation in this clinical trial, patients fully understand the trial content and sign the informed consent\n\nExclusion Criteria:\n\n* Pregnant or lactating women；\n* Known allergy to Romiplostim N01;\n* A history of severe thrombotic events or known risk factors for thrombosis or active thromboembolism requiring anticoagulation;\n* A history of platelet dysfunction or bleeding prone disease or severe bleeding (requiring more than 2 units of red blood cell infusion or a hematocrit drop of ≥10%) within 7 days prior to screening;\n* Chronic active hepatitis B and C;\n* Repeat or multiple transplantation or multiple organ transplantation;\n* HIV positive, EBV-DNA positive, CMV-DNA positive;\n* Have severe infection or complicated with serious heart, liver, lung, kidney, neurological or metabolic diseases;\n* A serious adverse event (Level 4 or 5) as defined by the Standard General Terminology for Adverse Events Version 4.0 occurred during the pre-treatment period;\n* Participants participate in another clinical study with any exploratory drug or device within 30 days prior to baseline visit; Observational studies are allowed;\n* Subjects with cognitive impairment or uncontrolled mental illness;\n* Subjects and\u002For authorized family members to refuse treatment with Romiplostim N01;\n* Those who are judged by the researchers as not suitable for inclusion (such as accompanying medical history, which may affect the safety of the subjects or it is estimated that the treatment cannot be adhered to due to financial problems).",{"count":81,"type":20},34,[83],"PHASE2","To evaluate the efficacy and safety of Romiplostim N01 for platelet recovery after umbilical cord blood transplantation (UCBT) in patients with hematological malignancies.",[28],"2024-11-15",{"date":88,"type":38},"2024-11-18",{"date":90,"type":20},"2024-12-01",{"date":92,"type":20},"2026-12-01",{"name":44,"class":45}]